drugset / Trial / NCT00461110
A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the maximum tolerated dose and assess the safety and tolerability of escalating doses of BMS-663513 when given in combination with either radiotherapy alone or radiotherapy plus paclitaxel and carboplatin.
Timeline
- Start
- 2008-01
- Primary completion
- 2009-04
- Completion
- 2009-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Urelumab | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | Urelumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Urelumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Urelumab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | Urelumab | Monoclonal antibody | 10 mg/kg | Intravenous |